Halozyme Therapeutics, Inc.
Every calculator, already run for HALO
Open the full toolkit →You have the numbers on HALO. Get the argument.
A written report on which of these readings actually decide the outcome for Halozyme Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering HALOAnalyst Price Target Disagreement for Halozyme Therapeutics, Inc.
Wall Street's bull case implies +2% from the current price; the bear case implies -32%. A 34% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED,…
HALO — frequently asked
Is HALO a buy right now?
Wall Street's consensus rating on Halozyme Therapeutics, Inc. is none across 9 analysts, with a mean price target of $88.22 (-14% vs. the current $103.12). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is HALO overvalued?
HALO trades at 36.2x trailing earnings, against a DCF fair value of $48 per share. The current price implies 16% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is HALO's next earnings date?
Halozyme Therapeutics, Inc. is next scheduled to report earnings around Nov 2, 2026. A full HALO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Halozyme Therapeutics, Inc.?
Analysts covering Halozyme Therapeutics, Inc. (HALO) range from a bear-case target of $70.00 to a bull-case high of $105.00, with a mean consensus target of $88.22 across 9 analysts. The spread of $35.00 (34% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Halozyme Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Halozyme Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full HALO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Halozyme Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.